Clinical Trial

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2021-06-17; most recent amendment 2026-07-09.
Status change: Recruiting → Active, Not Recruiting 2025-05-08
Status change: Active, Not Recruiting → Recruiting 2023-12-07
Status change: Recruiting → Active, Not Recruiting 2023-09-06
Status change: Not Yet Recruiting → Recruiting 2021-12-03
Trial Details
NCT Number NCT04939597
Lead Sponsor Children's Oncology Group
Conditions Central Nervous System Carcinoma
Enrollment 162 participants
Start Date 2022-05-10
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-13